COMP <GO>
HCAT vs MSFT // RETURN ON INVESTED CAPITAL (ROIC)
Health Catalyst Inc (NASDAQ) VS. Microsoft Corporation (NASDAQ) • 15-METRIC TALLY: HCAT 0
— MSFT 10
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: MSFT
LAST: $1.79 (-0.56%) • MKT CAP: $134.7M
roic
-35.00%
LAST: $530.14 (-0.16%) • MKT CAP: $3.94T
roic
26.54%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (HCAT VS. MSFT)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | HCAT | MSFT | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 67.66% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | -35.00% | 26.54% | -61.54 | MSFT | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 19.9x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -0.18% | 1.55% | -1.73 | MSFT | /fcf-yield <GO> |
| Operating Margin | -51.70% | 47.10% | -98.80 | MSFT | /operating-margins <GO> |
| Net Profit Margin | -57.20% | 41.17% | -98.37 | MSFT | /net-margins <GO> |
| Revenue Growth (YoY) | 1.50% | 17.91% | -16.41 | MSFT | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.70% | -0.70 | MSFT | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | 9.35 | -9.15 | MSFT | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 6/9 | -2.00 | MSFT | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 5.74% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 46.8 | 64.8 | -18.04 | MSFT | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.14 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 24.2x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $134.7M | $3.94T | -$3.94T | MSFT | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | HCAT REV | MSFT REV | HCAT GROSS % | MSFT GROSS % | HCAT FCF | MSFT FCF |
|---|---|---|---|---|---|---|
| FY 2026 | — | $331.84B | — | 67.9% | — | $66.99B |
| FY 2025 | $311.1M | $281.72B | — | 68.8% | -$237.0K | $71.61B |
| FY 2024 | $306.6M | $245.12B | — | 69.8% | $12.9M | $74.07B |
| FY 2023 | $295.9M | $211.91B | — | 68.9% | -$33.1M | $59.48B |
| FY 2022 | — | $198.27B | — | 68.4% | — | $65.15B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
HCAT // BETA —
MSFT // BETA 1.14